Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCR-7952
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
01
Overview
SCR-7952: sourced facts only. name: "In biochemical assay, SCR-7952 exhibited potent inhibitory activity on MAT2A enzyme with IC50 of 21 nM, which was more potent than AG-270 (IC50, 68 nM)." [DOI:10.1158/1538-7445.am2022-5434]; target: "In biochemical assay, SCR-7952 exhibited potent inhibitory activity on MAT2A enzyme with IC50 of 21 nM, which was more potent than AG-270 (IC50, 68 nM)." [DOI:10.1158/1538-7445.am2022-5434]; developer: "1Simcere Pharmaceutical Group, Shanghai, China." [DOI:10.1158/1538-7445.am2022-5434]; stage: "In the HCT-116 MTAP-/- xenograft model, SCR-7952 demonstrated robust anti-tumor activity and achieved 72% tumor growth inhibition (TGI) at 1 mpk, QD, which was more potent than AG-270 (TGI 56% at 200 mpk, QD)." [DOI:10.1158/1538-7445.am2022-5434]
02
Targets
MAT2A (Methionine adenosyltransferase 2A)
Beyond the preview
Go deeper on SCR-7952.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCR-7952.